NADPH oxidase enzymes in skin fibrosis: molecular targets and therapeutic agents
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Fibrosis is characterized by the excessive deposition of extracellular matrix components eventually resulting in organ dysfunction and failure. In dermatology, fibrosis is the hallmark component of many skin diseases, including systemic sclerosis, graft-versus-host disease, hypertrophic scars, keloids, nephrogenic systemic fibrosis, porphyria cutanea tarda, restrictive dermopathy and other conditions. Fibrotic skin disorders may be debilitating and impair quality of life. There are few FDA-approved anti-fibrotic drugs; thus, research in this area is crucial in addressing this deficiency. Recent investigations elucidating the pathogenesis of skin fibrosis have implicated endogenous reactive oxygen species produced by the multicomponent nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (Nox) enzyme complex. In this review, we discuss Nox enzymes and their role in skin fibrosis. An overview of the Nox enzyme family is presented and their role in the pathogenesis of skin fibrosis is discussed. The mechanisms by which Nox enzymes influence specific fibrotic skin disorders are also reviewed. Finally, we describe the therapeutic approaches to ameliorate skin fibrosis by directly targeting Nox enzymes with the use of statins, p47phox subunit modulators, or GKT137831, a competitive inhibitor of Nox enzymes. Nox enzymes can also be targeted indirectly via scavenging ROS with antioxidants. We believe that Nox modulators are worthy of further investigation and have the potential to transform the management of skin fibrosis by dermatologists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms of fibrosis: therapeutic translation for fibrotic disease
Wynn, T. A., & Ramalingam, T. R. (2012) · Nature Medicine · doi:10.1038/nm.2807 · Cited by 3,541 · cited 2×
“Damaged endothelial cells secrete cytokines to recruit and activate immune cells such as neutrophils, macrophages, T lymphocytes and B lymphocytes [71, 111, 112].”
Fibrotic disease and the TH1/TH2 paradigm
Wynn, T. A. (2004) · Nature Reviews Immunology · doi:10.1038/nri1412 · Cited by 1,765
Cucoranu, I., Clempus, R., Dikalova, A., Phelan, P. J., Ariyan, S., Dikalov, S., & Sorescu, D. (2005) · Circulation Research · doi:10.1161/01.res.0000187457.24338.3d · Cited by 786 · cited 1×
“There is also evidence of Nox involvement in heart: TGF-beta1 stimulates Nox4 generation of ROS leading to increased expression of ECM proteins (collagen and fibronectin), CTGF and differentiation of fibroblasts into myofibroblasts [26].”
Cytokine mediated tissue fibrosis
Borthwick, L. A., Wynn, T. A., & Fisher, A. J. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.09.014 · Cited by 375 · cited 1×
“Scleroderma is a complex connective tissue disorder characterized by the excessive deposition of ECM proteins in the skin and internal organs [19].”
The NOX toolbox: validating the role of NADPH oxidases in physiology and disease
Altenhöfer, S., Kleikers, P. W. M., Radermacher, K. A., Scheurer, P., Rob Hermans, J. J., Schiffers, P., Ho, H., Wingler, K., & Schmidt, H. H. H. W. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1010-9 · Cited by 371
Aoyama, T., Paik, Y.-H., Watanabe, S., Laleu, B., Gaggini, F., Fioraso-Cartier, L., Molango, S., Heitz, F., Merlot, C., Szyndralewiez, C., et al. (2012) · Hepatology · doi:10.1002/hep.25938 · Cited by 336
Laleu, B., Gaggini, F., Orchard, M., Fioraso-Cartier, L., Cagnon, L., Houngninou-Molango, S., Gradia, A., Duboux, G., Merlot, C., Heitz, F., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100773e · Cited by 243 · cited 1×
“GKT137831 is the first inhibitor fulfilling the key requirements needed in a Nox inhibitor, including high oral bioavailability, suitable toxicity profile, specificity for Nox enzymes, selectivity for Nox isoforms, and lack of antioxidant activity [58].”
Nox enzymes as novel targets for drug development
Lambeth, J. D., Krause, K.-H., & Clark, R. A. (2008) · Seminars in Immunopathology · doi:10.1007/s00281-008-0123-6 · Cited by 212 · cited 10×
“Furthermore, fibroblasts isolated from the lungs of patients with IPF generated increased H2O2 in response to TGF-beta1 and induced death of the respiratory epithelial cells [59, 102].”
InfluentialGianni, D., Taulet, N., Zhang, H., DerMardirossian, C., Kister, J., Martinez, L., Roush, W. R., Brown, S. J., Bokoch, G. M., & Rosen, H. (2010) · ACS Chemical Biology · doi:10.1021/cb100219n · Cited by 192 · cited 2×
“Each Nox1 and Nox3 also have their own unique six transmembrane-spanning alpha helix catalytic subunit, similar to gp91phox in Nox2 enzyme [4, 35].”
Manoury, B., Nenan, S., Leclerc, O., Guenon, I., Boichot, E., Planquois, J.-M., Bertrand, C. P., & Lagente, V. (2005) · Respiratory Research · doi:10.1186/1465-9921-6-11 · Cited by 186
Ebselen, a Glutathione Peroxidase Mimetic Seleno-organic Compound, as a Multifunctional Antioxidant
Nakamura, Y., Feng, Q., Kumagai, T., Torikai, K., Ohigashi, H., Osawa, T., Noguchi, N., Niki, E., & Uchida, K. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109641200 · Cited by 161
miR-196a Downregulation Increases the Expression of Type I and III Collagens in Keloid Fibroblasts
Kashiyama, K., Mitsutake, N., Matsuse, M., Ogi, T., Saenko, V. A., Ujifuku, K., Utani, A., Hirano, A., & Yamashita, S. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.22 · Cited by 139 · cited 2×
“The etiology of keloids is not fully understood and keloids can be challenging to manage [49].”
Nox1, 2, 4, 5: Counting out oxidative stress
Wingler, K., Hermans, J., Schiffers, P., Moens, A., Paul, M., & Schmidt, H. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01249.x · Cited by 113 · cited 1×
“However, the potential use of these small compounds as treatments for fibrotic diseases is limited as they lack specificity and influence the activation of several other enzymes [4, 109].”
BLOXHAM, D. P. (1979) · Biochemical Society Transactions · doi:10.1042/bst0070103 · Cited by 19
Cited by
Morry, J., Ngamcherdtrakul, W., & Yantasee, W. (2017) · Redox Biology · doi:10.1016/j.redox.2016.12.011 · Cited by 333
The role of myofibroblasts in wound healing
Hinz, B. (2016) · Current Research in Translational Medicine · doi:10.1016/j.retram.2016.09.003 · Cited by 328
Reactive oxygen species and fibrosis: further evidence of a significant liaison
Richter, K., & Kietzmann, T. (2016) · Cell and Tissue Research · doi:10.1007/s00441-016-2445-3 · Cited by 322
“and growth factors (Barnes and Gorin 2011; Babalola et al. 2014; Paik et al. 2014) indicating common feed-forward and feedback mechanisms (Fig.”
BackgroundYao, Y., Zhang, H., Wang, Z., Ding, J., Wang, S., Huang, B., Ke, S., & Gao, C. (2019) · Journal of Materials Chemistry B · doi:10.1039/c9tb00847k · Cited by 318
Therapeutic potential of nadph oxidase 1/4 inhibitors
Teixeira, G., Szyndralewiez, C., Molango, S., Carnesecchi, S., Heitz, F., Wiesel, P., & Wood, J. M. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13532 · Cited by 163
Metadata
- Authors
- Babalola, O., Mamalis, A., Lev-Tov, H., & Jagdeo, J.
- Venue
- Archives of Dermatological Research
- Published
- 2013-10-24
- Volume
- 306
- Issue
- 4
- Pages
- 313-330
- ISSN
- 0003-9187 (ISSN-L)
- 0340-3696
- 1432-069X
- OpenAlex
- W2095299402
- Cited by
- 47
- References
- 14
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.